

# ERLEADA (apalutamide)

### **Pre - PA Allowance**

None

## **Prior-Approval Requirements**

Age 18 years of age or older

**Gender** Male

**Diagnoses** 

Patient must have **ONE** of the following:

- 1. Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
- 2. Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC)

#### **AND ONE** of the following for **ALL** indications:

- 1. Patient is receiving gonadotropin-releasing hormone (GnRH) analog
- 2. Patient has had a bilateral orchiectomy

#### **AND ALL** of the following for **ALL** indications:

- NO dual therapy with another androgen receptor inhibitor (see Appendix 1)
- 2. Prescriber agrees to advise males with female partners of reproductive potential to use effective contraception during treatment and for 3 months after the last dose of Erleada

### **Prior - Approval Limits**

**Quantity** 240 mg per day

**Duration** 12 months

## Prior – Approval Renewal Requirements

Same as above

## Prior - Approval Renewal Limits

Same as above



# ERLEADA (apalutamide)

## **Appendix 1 - List of Androgen Receptor Inhibitors**

Generic Name	Brand Name
abiraterone	Yonsa
abiraterone	Zytiga
abiraterone/niraparib	Akeega
apalutamide	Erleada
darolutamide	Nubeqa
enzalutamide	Xtandi
nilutamide	Nilandron